Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence.
about
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysisImmunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.HPV infection and cervical disease: a review.Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women.HPV vaccine acceptance, utilization and expected impacts in the U.S.: Where are we now?Community-based interventions to improve HPV vaccination coverage among 13- to 15-year-old females: measures implemented by local governments in Japan.Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence.Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancerHPV Infection and Cervical Screening in Socially Isolated Indigenous Women Inhabitants of the Amazonian Rainforest.The prevention of infection-associated cancersHigh Burden of Human Papillomavirus (HPV) Infection among Young Women in KwaZulu-Natal, South AfricaCosts of cervical cancer screening and treatment using visual inspection with acetic acid (VIA) and cryotherapy in Ghana: the importance of scale.Squamous cell papilloma of the conjunctiva due to human papillomavirus (HPV): presentation of two cases and review of literature.Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.Diversity and uncommon HPV types in HIV seropositive and seronegative women attending an STI clinicModeling preventative strategies against human papillomavirus-related disease in developed countriesHuman papilloma virus (HPV) vaccination in childhood: challenges and perspectives.Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.Accuracy of parental reports of children's HPV vaccine status: implications for estimates of disparities, 2009-2010.The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps.Human papillomavirus vaccines: where do they fit in HIV-infected individuals?Genital Human Papillomavirus Infection in Indian HIV-Seropositive Men Who Have Sex With Men.The prevalence of HPV infections in HPV-vaccinated women from the general population.Cervical cancer in Zimbabwe: a situation analysis.Human papillomavirus types in HIV seropositive men with penile warts in Johannesburg, South Africa.High risk human papillomavirus prevalence and genotype distribution among women infected with HIV in Manaus, Amazonas.Type-specific human papillomavirus infections and Pap test findings in Inuit and non-Inuit women in Nunavut, Canada.Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention.
P2860
Q26863193-3F6762FA-3EF0-4CDB-B1B0-70A7CF896109Q31159398-8ABB78B3-2987-4860-8971-6FD16288B3CFQ33159907-05473D72-4638-432F-BF84-B9DF04E2CCF6Q33761437-516648EC-227C-4E68-A248-1CCE295EA444Q34440994-7A1693C0-B804-4D8B-8CB4-9B22FA613C40Q35073245-A1AFB73E-EE85-4D96-AA41-54B6DA3A6282Q35121855-B9F1BC14-045E-4C94-898D-2E6FD18E3663Q35258843-CC893510-7F43-49F3-AFF9-3718F0110E56Q35711091-5740C580-82F0-4E15-8362-0304FE8D6B98Q35857515-6A8CA027-6A60-40B2-BDFB-F4DD8EAEB7EDQ35898044-BF240864-F6D7-44B1-AE3A-ABF9E69AAA5FQ36195826-A7BE0A1E-F36C-4CB4-9FEF-1D85B0F0DDF2Q36286957-15B257F6-8591-4DFB-BE8D-AD3978019712Q36978399-BDD83F57-F81D-4652-9423-222B7A42C16CQ37162288-460F3C3C-F4FC-46EB-9504-EA807AA1E589Q37198208-C6BD0956-54BE-4F6F-9D25-D536D3F5F1FCQ37422821-93BDBB75-E0F8-4AA9-BB71-157DA606A2BDQ37616577-FAACE3FA-D72C-4CB1-8937-B46EB1762DE6Q37696102-16185F2B-69A5-4283-96CD-0E78AD9F8DFAQ37912062-FA4BE023-0E02-411E-A6FB-6AF0147A8B08Q38022478-0647546A-D14C-4ACD-8743-40A5DC483B93Q38971877-AF2690B9-F159-48E2-A362-1188228DC841Q40291505-CD7F7431-58FB-4F04-B918-B414D9225600Q41990954-22AAE312-11F4-482D-A8D0-FB8A601FA144Q44475217-C783BD71-F0D5-4F1F-AEA9-BDBA40BD51B0Q49900329-F3EC9FC1-B092-42F3-9B84-1C2E7C103EB5Q54961163-B444F261-45AE-41D5-992F-C83BC3D4D641Q55385410-B18BB188-D450-4DC2-8181-1B4274F3D165
P2860
Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy, duration of immunity ...... ion: a review of the evidence.
@en
Efficacy, duration of immunity ...... ion: a review of the evidence.
@nl
type
label
Efficacy, duration of immunity ...... ion: a review of the evidence.
@en
Efficacy, duration of immunity ...... ion: a review of the evidence.
@nl
prefLabel
Efficacy, duration of immunity ...... ion: a review of the evidence.
@en
Efficacy, duration of immunity ...... ion: a review of the evidence.
@nl
P2093
P1433
P1476
Efficacy, duration of immunity ...... ion: a review of the evidence.
@en
P2093
Angela Bechini
Paolo Bonanni
Sara Boccalini
P304
P356
10.1016/J.VACCINE.2008.10.085
P407
P478
27 Suppl 1
P577
2009-05-01T00:00:00Z